Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3203 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | NRG Oncology King Faisal Specialist Hospital & Research Center | Ongoing | CISPLATIN (CISPLATYL ) | 2 | NRG-HN002 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Study of Aflibercept in Uveitic Macular EDema (SAUD study) | King Khalid Eye Specialist Hospital | Rejected | Aflibercept | 3 | 18176/ | King Khaled Eye Specialist Hospital (Riyadh) |
| A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers | KAIMRC | Ongoing | vaccine ChAdOx1 MERS | 1 | CT18/004/R | King Abdulaziz Medical City NG (Riyadh) |
| Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Hikma | Rejected | Dasatinib | 2 | LPI-JOR-LEB-KSA-TUN- | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease. | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3201 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3204 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents | Sanofi | Ongoing | Insulin glargine/Lixisenatide | 3b | LPS15017 | King Fahad Medical City (Riyadh) |
| A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease | Janssen-Cilag International NV | Ongoing | Guselkumab | 2 | CNTO1959CRD3001 | King Abdullah Medical City (Makkah), King Abdulaziz Medical City NG (Riyadh) |
| A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) | Astrazeneca | Ongoing | Ticagrelor | 3 | D5136C00009 | King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.